Samsung KoAct Bio-Healthcare Active ETF Surpasses 200 Billion Won in Net Assets
Samsung Active Asset Management's 'KoAct Bio-Healthcare Active' ETF has reached a net asset value of 202 billion won since its listing, achieving the highest return rate among domestic bio-healthcare ETFs. This ETF invests in bio-healthcare companies reflecting the aging society and advancements in AI technology to pursue stable performance. Its main portfolio includes companies like AbClon, Alteogen, and Samsung Biologics, covering a comprehensive range of the bio-healthcare value chain.
The growth of the healthcare industry globally enhances the attractiveness of this ETF, leading to a steady inflow of investment. Notably, this ETF differentiates itself by actively selecting investment stocks rather than following established indices. Samsung Active Asset Management plans to expand its differentiated active ETF lineup through the KoAct series. As AI technology and aging trends drive high growth in the bio-healthcare industry, investment demand is expected to continue rising.
Related ETF
Related News
Samsung Active Bio ETF Surpasses 200 Billion Won in Net Assets - SBS Biz[Provided by Samsung Active Asset Management (Samsung Active Asset Management)=Yonhap News] Samsung Active Asset Management announced today (5th) that its 'KoAct Biohealthcare Active' Exchange-Traded Fund (ETF) has exceeded 200 billion won in net assets. This ETF is Korea's first active ETF in the bio and healthcare sector and was listed in 2023. Active ETFs track indices ...
Related ETF
화이트페이퍼20 hours ago
KoAct Bio Healthcare Active ETF, Surpasses 200 Billion KRW Net Assets - White Paper[White Paper= Reporter Go Su-ah] Samsung Active Asset Management announced on the 5th that 'KoAct Bio Healthcare Active,' Korea's first bio active ETF investing in the bio-healthcare sector, has surpassed 200 billion KRW (202 billion KRW) in net assets. This ETF is the first product introduced under Samsung Active Asset Management’s independent ETF brand, ‘KoAct’. Since its listing in August 2023, it has experienced steady inflows and rapid growth. The portfolio covers a wide range of areas within the healthcare value chain, including pharmaceuticals, biotech, medical devices, cosmetic devices, and AI diagnostics. As of the 4th, the yield is at 10.2% over the last month.
Related ETF
Samsung Active Bio ETF, Net Assets 200 Billion…"High Growth Expectations ↑"Samsung Active Bio ETF, Net Assets 200 Billion…"High Growth Expectations ↑" (Seoul = Yonhap News) Reporter Kim Tae-kyun = Samsung Active Asset Management announced on the 5th that its 'KoAct Bio Healthcare Active' Exchange Traded Fund (ETF) exceeded 200 billion won in net assets. This ETF is an active ETF in the bio and healthcare sector...
Related ETF
'KoAct BioHealthcare Active' Exceeds 200 Billion Won in Net Assets - EdailySamsung Active Asset Management announced on the 5th that 'KoAct BioHealthcare Active', the country's first bio active exchange-traded fund (ETF), has exceeded 200 billion won in net assets, reaching 202 billion won. (Photo = Samsung Active Asset Management) This ETF is launched under Samsung Active Asset Management's independent ETF brand 'KoAct'...
Related ETF